循环肿瘤细胞在乳腺癌新辅助化疗疗效评估中的应用和展望

Application and prospect of circulating tumor cells in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer

随着对乳腺癌发病机制及疾病进展的深入研究,新辅助化疗已然成为炎性乳腺癌,局部晚期乳腺癌和选择保乳手术治疗患者的首选治疗措施。因此,新辅助化疗的疗效评估成为治疗的关键环节。临床上大多以影像学资料作为首选方法,血清学指标的应用少之又少。循环肿瘤细胞(CTCs)作为一项日趋成熟的血清学标志物,具有取材方便,检测手段易行,机体创伤小,可重复监测等优点,与传统影像学资料相比,CTCs能够较早发现微转移,无射线损伤等优势,应用前景广泛。本文就CTCs在乳腺癌新辅助化疗疗效评估中的价值作一综述。

With the in-depth study of the pathogenesis and disease progression of breast cancer,neoadjuvant chemotherapy has become the preferred treatment for patients with inflammatory breast cancer,locally advanced breast cancer and optional early surgical treatment.Therefore,the evaluation of the efficacy of neoadjuvant chemotherapy has become a key link in the treatment.Imaging data is the preferred method in clinic,but the application of serological indexes is rare.Circulating tumor cells(CTCs),as an increasingly mature serological marker,have the advantages of convenient sampling,easy detection method,small body trauma,repeatable monitoring and so on.Compared with traditional imaging data,CTCs can detect micrometastasis earlier and have no radiation damage and other advantages,so it has a broad application prospect.This article reviews the value of CTCs in the evaluation of neoadjuvant chemotherapy for breast cancer.